These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22044496)

  • 1. Targeting the aldosterone pathway in cardiovascular disease.
    Gustafsson F; Azizi M; Bauersachs J; Jaisser F; Rossignol P
    Fundam Clin Pharmacol; 2012 Feb; 26(1):135-45. PubMed ID: 22044496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.
    Galuppo P; Bauersachs J
    Eur J Clin Invest; 2012 Oct; 42(10):1112-20. PubMed ID: 22536780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoids in the heart and vasculature: new insights for old hormones.
    Lother A; Moser M; Bode C; Feldman RD; Hein L
    Annu Rev Pharmacol Toxicol; 2015; 55():289-312. PubMed ID: 25251996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptors in the metabolic syndrome.
    Zennaro MC; Caprio M; Fève B
    Trends Endocrinol Metab; 2009 Nov; 20(9):444-51. PubMed ID: 19800255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding view of aldosterone action, with an emphasis on rapid action.
    Vinson GP; Coghlan JP
    Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):410-6. PubMed ID: 20409082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone and cardiovascular disease.
    Gaddam KK; Pimenta E; Husain S; Calhoun DA
    Curr Probl Cardiol; 2009 Feb; 34(2):51-84. PubMed ID: 19135616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone and the kidney.
    Fourkiotis VG; Hanslik G; Hanusch F; Lepenies J; Quinkler M
    Horm Metab Res; 2012 Mar; 44(3):194-201. PubMed ID: 22161301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone, mineralocorticoid receptors and vascular inflammation.
    Funder JW
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):263-9. PubMed ID: 15134827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
    Pasquale PD; Stefano GD; Paterna S
    Ital Heart J; 2000 Sep; 1(9):595-604. PubMed ID: 11130838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride.
    Teiwes J; Toto RD
    Am J Hypertens; 2007 Jan; 20(1):109-17. PubMed ID: 17198922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
    Oestreicher EM; Martinez-Vasquez D; Stone JR; Jonasson L; Roubsanthisuk W; Mukasa K; Adler GK
    Circulation; 2003 Nov; 108(20):2517-23. PubMed ID: 14581407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid effects of aldosterone on vascular cells: clinical implications.
    Lösel R; Schultz A; Boldyreff B; Wehling M
    Steroids; 2004 Aug; 69(8-9):575-8. PubMed ID: 15288772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone as a cardiovascular risk factor.
    Rossi G; Boscaro M; Ronconi V; Funder JW
    Trends Endocrinol Metab; 2005 Apr; 16(3):104-7. PubMed ID: 15808807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
    Heerspink HJ
    Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology.
    Funder JW; Mihailidou AS
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):2-6. PubMed ID: 19026715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone and end-organ damage.
    Marney AM; Brown NJ
    Clin Sci (Lond); 2007 Sep; 113(6):267-78. PubMed ID: 17683282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation.
    Young MJ
    Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):174-80. PubMed ID: 18277151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Aldosterone as an endogenous cardiovascular toxin and the options for its therapeutic management].
    Horký K
    Vnitr Lek; 2011 Dec; 57(12):1012-6. PubMed ID: 22277034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid actions of aldosterone in vascular health and disease--friend or foe?
    Skøtt O; Uhrenholt TR; Schjerning J; Hansen PB; Rasmussen LE; Jensen BL
    Pharmacol Ther; 2006 Aug; 111(2):495-507. PubMed ID: 16413609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon?
    Farman N; Maubec E; Poeggeler B; Klatte JE; Jaisser F; Paus R
    Exp Dermatol; 2010 Feb; 19(2):100-7. PubMed ID: 19925636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.